87
Participants
Start Date
December 14, 2018
Primary Completion Date
July 15, 2022
Study Completion Date
December 2, 2022
AL101
"AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously"
Radboud University, Nijmegen
Memorial Sloan Kettering Cancer Center, New York
University of Maryland School of Medicine, Baltimore
Sylvester Comprehensive Cancer Center, Miami
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Rabin Medical center, Petah Tikva
Mayo Clinic Hospital, Rochester
MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
USC Norris Comprehensive Cancer center, Los Angeles
Institut Gustave Roussy, Villejuif
Fred Hutchinson Cancer Research Center, Seattle
Massachusetts General Hospital, Boston
Tom Baker Cancer Centre, Calgary
Hamilton Health Sciences Juravinski Cancer Centre, Hamilton
London Health Sciences Center, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Ayala Pharmaceuticals, Inc,
INDUSTRY